Company Cash Volume: Nautilus Biotechnology Inc (NAUT)

Brandmark of Nautilus Bio (NAUT)

Cash dynamics at Nautilus Biotechnology (NAUT) correlate with the company's plans to monetize its protein analysis system for the creation of personalized therapies. The current level of this metric stands at 0.09, supporting the development of the AI ecosystem and long-term B2B contracts with research centers. However, intense competition in the proteomics field and the expansion of DNA sequencing behemoths are forcing the company to strictly control its liquid reserves.

NAUT - nautilus.bio Company Cash Balance over the range 07/04/2022 - 11/21/2026

Summary analytical data breakdowns for nautilus.bio (NAUT)

General company analysis:NAUT Nautilus Bio
Signature product of Nautilus Biotechnology

For Nautilus Biotechnology (NAUT), which is developing a complex proteomic platform, access to liquidity remains a critical survival factor until the company reaches the break-even point. An analysis of the cash reserve allows for an assessment of the deposit volume that either generates interest income or covers operating losses, determining the financial stability of this high-risk biotech asset amid fierce competition and high interest rates.

Competitors of Nautilus Biotechnology (NAUT)

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume